Diary - News
All news Poxel Announces Imeglimin Phase 2b Initiation in Japan
POXEL SA, a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today provided an update on the clinical development of its two lead pipeline assets: Imeglimin, the first in a new class of oral anti-diabetic agents, and PXL770, a direct activator of the adenosine monophosphate-activated kinase (AMPK).
The first Phase 2b clinical trial site for Imeglimin has been opened in Japan, starting the planned rapid late-stage clinical development program for Imeglimin in the Japanese market.
For PXL770, preparations for the start of a Phase 1 trial in Germany are on track to obtain first clinical data by mid-2016.
By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree